Clinical chronotolerance to anticancer drugs: relevance for dose-intensity.
There is increasing experimental and clinical data to suggest that the timing of chemotherapy may be important for both toxicity and response. The availability of programmable infusion pumps has made the clinical testing and application of circadian scheduling possible. This paper provides an overview regarding the current clinical data with some references to the experimental studies. Further progress in this area is dependent on a better understanding of the mechanisms involved and continued high quality clinical trials.
Bjarnason
G A
GA
Department of Medicine, University of Toronto, Ontano, Canada.
D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005467:Floxuridine / Q000494:pharmacology; D006801:Humans; D015122:Mercaptopurine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D010984:Platinum / Q000494:pharmacology
D000470:Alkaloids; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005467:Floxuridine; D010984:Platinum; D015122:Mercaptopurine; D008727:Methotrexate